Back to top
more

Cidara Therapeutics (CDTX)

(Delayed Data from NSDQ)

$12.63 USD

12.63
199,562

-0.37 (-2.85%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $12.59 -0.04 (-0.32%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CDTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cidara Therapeutics, Inc. [CDTX]

Reports for Purchase

Showing records 1 - 20 ( 143 total )

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

01/30/2024

Daily Note

Pages: 3

REZZAYO Enters Into a Key Market in Europe; Next Milestone is ReSTORE Data Readout in China in 2Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

12/22/2023

Daily Note

Pages: 3

REZZAYO Now Approved in Europe; Phase 3 Top-line Readout in 2Q24 Could Support Approval in China

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

12/07/2023

Daily Note

Pages: 3

Phase 3 ReSTORE Trial Completed Enrollment in China; Topline Data Expected in 2Q24; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

11/06/2023

Company Report

Pages: 8

3Q Recap; REZZAYO''s EC Approval Expected By Year-End 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

10/16/2023

Daily Note

Pages: 6

IDWeek 2023 Presentations Highlight CD388''s Protection Against Influenza Regardless of Immune Status; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

10/13/2023

Daily Note

Pages: 3

We Anticipate REZZAYO''s European Approval For Invasive Candidiasis Based on CHMP''s Positive Opinion; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

09/22/2023

Daily Note

Pages: 7

RD Day Highlights DFC''s Potential in Oncology; First-in - Human Study Expected to Begin in Mid-2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/07/2023

Daily Note

Pages: 3

Janssen’s CD388 Collaboration Opt-in Is a Net Positive

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

08/07/2023

Company Report

Pages: 8

2Q Recap; REZZAYO Now Available in the U.S.; Cidara to Provide Updates on Cloudbreak Programs in RD Day; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/01/2023

Daily Note

Pages: 3

REZZAYO Commercial Launch Announced By U.S. Partner Melinta; RD Day to Update Cloudbreak Programs; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

07/21/2023

Daily Note

Pages: 4

CD388 Collaborative Agreement With Janssen Could Be Impacted By Business Prioritization Plan; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/26/2023

Daily Note

Pages: 4

CD421 Shows Potential Against Other Oncology Treatment Modalities; CD388 Receives Fast Track Designation; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/15/2023

Company Report

Pages: 8

1Q Recap; Working Towards New Milestones After REZZAYO''s Approval; IND Filing of First Oncology DFC in 2024; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/24/2023

Company Report

Pages: 8

4Q Recap: Financing and Labeling Concerns Overshadow REZZAYO Approval; Focus to Shift to CD388 for Influenza

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/23/2023

Company Report

Pages: 6

FDA Approves REZZAYO for the Treatment of Candidemia and Invasive Candidiasis in Adults: Lower PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/08/2023

Daily Note

Pages: 4

CBO-212 Shows Potential Versus Other Oncology Therapeutic Modalities in Presentation at ESMO-TAT; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

03/01/2023

Daily Note

Pages: 4

Positive Interim Data on CD388 From Influenza Challenge Study; Rezafungin Approaching March 22 PDUFA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

01/25/2023

Company Report

Pages: 6

Antimicrobial Drugs AdCom Votes 14-1 in Favor of Rezafungin, Despite Concerns Raised in FDA Briefing Docs; PT to $6.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

01/06/2023

Daily Note

Pages: 3

First Cloudbreak Oncology Program Unveiled; Rezafungin''s January 24 AdCom Is the Next Key Stock Catalyst; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Cidara Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

12/02/2022

Daily Note

Pages: 5

Foundational CoM U.S. Patent Granted For CD388; Lancet Publication Highlights Rezafungin Pivotal Dataset; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party